The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark of Alzheimer's disease (AD). Curcumin has been reported to display anti-amyloidogenic activity, not only by inhibiting the formation of new Aβ aggregates, but also by disaggregating existing ones. However, the uptake of Curcumin into the brain is severely restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), modified with g7 ligand for BBB crossing. We performed in depth analyses of possible toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro using primary hippocampal cell cultures. Our results show no apparent toxicity of the formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded 3 NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a promising future approach in the treatment of AD.
Introduction
Alzheimer's disease (AD) is the most common cause of dementia among an estimated prevalence of 46.8 million people worldwide suffering from some form of dementia in 2015 (www.alz.co.uk/research/world-report-2016). Clinically, AD shows strong anterograde amnesia and a reduction of semantic knowledge. Furthermore, changes in personality and temper were reported (Butters et al., 1987) . AD is a multi-factorial neurodegenerative disorder pathologically characterized by deposits of β-amyloid (Aβ) in senile plaques, intracellular neurofibrillary tangles (NFTs) comprised of hyper-phosphorylated aggregates of microtubule associated with tau protein, synaptic dysfunction, and neuronal death The amyloid precursor protein (APP) is a transmembrane polypeptide of 770 amino acids. In its physiological form, it is known for neurotrophic activity, while in AD, a pathological deposition of a 42 amino acid long cleavage product of APP, Aβ1-42 occurs. Under physiological conditions, APP is processed into non-aggregating peptides by α-secretases.
Genetic predisposition and/or environmental factors lead to differential processing of APP by β-and γ-secretases in AD (Vassar et al., 1999) , which results in the formation of mainly extracellular Aβ aggregates. The Aβ monomers form dimers, oligomers, protofibrils and mature fibrils. Aβ modifications like phosphorylation have been shown to increase aggregation and toxicity (Kumar and Walter, 2011) . 4 Amyloid plaques are big and inhomogeneous aggregates of Aβ, other peptides, and also AGE's (Advanced Glycation endproducts), which are built by non-enzymatic glycosylation.
The plaques cause microglial activation and neuroinflammation. In addition or as result, synaptic loss is well described and has been attributed to a combination of toxic effects such as, among others, increased oxidative stress, synaptic Aβ toxicity, and/or zinc sequestration by Aβ. Synaptic loss as well as a decrease in overall cell number both correlate strongly with cognitive impairment in AD (Butterfield, 1997) .
The diarylheptanoid Curcumin (Cur) is the main Curcuminoid found in the rhizome of the Turmeric/Curcuma longa plant. The root contains about 3-5 % Curcuminoids of which between 50-60 % are Cur with its main conformation (1,7-Bis-(4-hydroxy-3-methoxyphenyl)-hepta-1,6-dien-3,5-dion). A variety of physiological effects have been described for Cur in the last years. For example, Cur was reported to act as antioxidant due to its ability to neutralize radicals by two phenolic groups. Further, Cur has been shown to activate Nrf2 (Nuclear factor 2) resulting in the increased expression of the antioxidant responsive element (ARE) (Esatbeyoglu et al., 2012) . In addition, Cur has been shown to act anti-inflammatory by modulation of NfκB (Nuclear factor κB) signaling (Lin et al., 1997) . Most importantly, Cur was reported to possess anti-amyloidogenic properties. Cur can not only inhibit the formation of new Aβ aggregates but also disaggregate existing ones (Yang et al., 2005) . Additionally, increased neuronal cell viability and neurite formation was reported (Ray and Lahiri, 2009 ).
Unfortunately, Cur displays a low bioavailability and solubility. To overcome these limitations, which strongly hamper the applicability in clinical use of Cur, different drug delivery systems were investigated as strategies to stabilize the active, to reduce its metabolism and to prolong its circulation within the body, thus achieving more bioavailable formulations of Cur. In fact, Cur was encapsulated in liposomes, solid lipid microparticles, or 5 nanoparticles using both natural (i.e chitosan) or synthetic polymers (polylactide-coglycolide: PLGA, poly(n-butyl cyanoacrylate): PBCA). These nanoformulations were developed for preclinical studies on cancer, inflammation, wound healing, and other pathological conditions, which demonstrated enhanced therapeutic efficacies, when nanoformulation strategies were applied in comparison with free Cur (Lazar et The properties of Cur against inflammation and oxidative stresses were also investigated with references to brain diseases, in which these events represent both a pathological hallmark and possible causes of the progression of the diseases. Above physico-chemical "negative"
properties of Cur, another major issue, considering the application in brain diseases, consists of the poor penetration of Cur across the Blood-Brain Barrier (BBB) (Anand et al., 2007) .
The BBB describes the physiological barrier between the blood circulatory system and the central nervous system (CNS). The physiological function of the BBB is of major importance for maintaining a normal brain environment enabling the tight regulation of ion hemostasis and also protecting the CNS from circulating pathogens or toxins (Abbott et al., 2010) . The development of new strategies to enhance Cur brain delivery based on colloidal carriers is of great importance, since engineered nanocarriers can protect drugs and deliver them across the BBB to target brain cells in a non-invasive way (Tosi et al., 2008) . Recently, the research in the area of carriers loading with Cur and surface modified to target the BBB as potential tools to transport the active into the brain is on growing (Yallapu et (Mundargi et al., 2008) , as confirmed by a number of marketed products (i.e., Lupron Depot, Nutropin Depot). Here, Cur loaded PLGA g7-NPs were tested for toxicity, targeted delivery, and biological activity using an in vitro model for AD, thus opening the pave for the future applications in in vivo animal model for evaluation of the efficacy in AD management.
Materials and Methods

Materials
Poly(D,L-lactide-co-glycolide) (PLGA,RG503H, MW near to 11,000) was used as received from the manufacturer (Boehringer-Ingelheim, Ingelheim am Rhein, Germany). Gly-L-Phe- Unless otherwise indicated, all other chemicals were obtained from Sigma-Aldrich.
Methods
Preparation of nanoparticles
Cur loaded NPs (g7-NPs-Cur) were prepared by oil-in-water simple emulsion/solvent evaporation method as described in literature with some modifications in the preparation procedure (Mainardes et al., 2005; Bondioli et al., 2010) . Briefly, a mixture composed by g7-PLGA (9 mg), PLGA (91 mg) and Cur (5 mg, 5% w/w dry weight of polymer) were dissolved in 3 mL of dichloromethane. The polymer/drug organic solution was emulsified in 12 mL of 1% w/v aqueous solution of PVA under sonication (55 W for 60 sec) at 5°C. Then, the emulsion was mechanically stirred (1,500 rpm) for at least 3 h (RW20DZM, Janke&Kunkel, IKA-Labortechnik, Staufen, Germany) at r.t. until complete evaporation of the solvent. As control, empty (NPs) and empty functionalized nanoparticles (g7-NPs) were formulated applying the same technology.
Purification and collection of the NPs
All NPs preparations were purified by an ultracentrifugation process carried out at 17,000 rpm for 10 min (4°C; Sorvall RC28S, Dupont, Brussels, Belgium) to remove the un-formed 8 material and the free surfactant fraction. The NPs were washed three times with water, resuspended in water (5 mL) and freeze-dried (-60°C, 1x10 -3 mm/Hg; LyoLab 3000, HetoHolten) by using D-(+)-trehalose (Fluka-Sigma-Aldrich) as cryo-protectant (1:1 w/w polymer/trehalose ratio). The yield (Yield%) was calculate as follows:
Sfd is the amount (mg) of freeze dried samples (excluded residual PVA and anhydrous trehalose) and Ctot is the total amount (mg) of polymer and Cur weighted for the preparation.
Atomic force microscopy
Atomic force microscopy (AFM) was used to clarify the morphology of the samples. The atomic force microscopical observations were performed with an Atomic Force Microscope (Park Instruments, Sunnyvale, CA, USA) at about 20°C operating in air and in Non-Contact (NC) mode using a commercial silicon tip-cantilever (high resolution noncontact "GOLDEN"
Silicon Cantilevers NSG-11, NTMDT, tip diameter = 5-10 nm; Zelenograd, Moscow, Russia) with stiffness about 40 Nm−1 and a resonance frequency around 170 kHz. After the purification, the samples were dispersed in distilled water and applied on a freshly cleaved mica disk (1 cm × 1 cm); 2 min after the deposition, the water excess was removed using blotting paper. The AFM images were obtained with a scan rate 1 Hz and processed using a program obtained from Gwyddion (Department of Nanometrology, Czech Metrology Institute, Brno, Czech Republic). Images were flattened using second-order fitting to remove [sample tilt] background curvature and slope from the images.
Particle Size and Z-potential analysis
The mean particle size (Z-average) and the polydispersivity index (PDI) were determined at r.t. by photon correlation spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern, UK; Laser 9 4 mW He-Ne, 633 nm, Laser attenuator Automatic, transmission 100-0.0003%, Detector
Avalanche photodiode, Q.E. > 50% at 633 nm). The Z-potential (-pot) was measured using the same equipment with a combination of laser Doppler velocimetry and phase analysis light scattering (PALS). All the data are the means of the least three determinations carried out for each preparation lot, referring to a suspension of NPs in distilled water before and after lyophilization.
Determination of the amount of PVA residual
As the residual PVA associated with the NPs could affect the physical properties and the cellular uptake, the amount of PVA was determined by a colorimetric method based on the formation of the colored complex between two adjacent hydroxyl groups of PVA and an iodine molecule (Joshi et al., 1979) . Briefly, 5 mg of a freeze-dried sample were solubilized in 1 mL of DCM. Then, 2 mL of distilled water were added and the organic solvent was evaporated at r.t. under stirring (2 h). The suspension was filtered (cellulose nitrate filter, porosity 0.45 m, Sartorius, Firenze, Italy) to remove the polymeric residue and 1 mL of the aqueous solution was treated with 2 mL of 0.5 M NaOH for 15 min at 60°C. The solution was neutralized with 900 L of 1 N HCl and the volume adjusted to 5 mL with distilled water.
Then, 3 mL of a 0.65 M solution of boric acid, 0.5 mL of a solution of I2/KI (0.05 M/0.15 M), and 1.5 mL of distilled water were added. PVA concentration was determined measuring the absorbance at 690 nm after 15 min incubation at r.t. in comparison with a standard plot of PVA prepared under the same experimental conditions.
Determination of drug loading capacity and encapsulation efficiency
Cur loaded into g7-NPs-Cur was extracted and quantified by high performance liquid chromatography (HPLC). Briefly, an exact amount of NPs (about 1 mg) was solubilized into 0.5 mL of chloroform by using a bath sonicator for 5 min. Then, 4 mL of isopropylic alcohol were added to precipitate the polymer. The mixture was filtrated through PTFE filter ( were recorded and analyzed using a JASCO software (JascoBorwin 1.5) and the concentration was calculated using the calibration curve previously set up (linearity was assumed in the range 0.3-9.5 g/mL; r2 = 0.9951). The encapsulation ability of NPs was evaluated considering the encapsulation efficiency (EE%) and the loading capacity (LC%) calculated using the following equations:
where D is the amount of the encapsulated drug, Td is the amount of drug added for the preparation and W is the weight of NPs (polymer + drug).
All the data are expressed as the mean of at least three determinations.
In vitro release studies
For each time point, an exact amount of g7-NPs-Cur (about 2 mg) was suspended in 1 mL of a 50% v/v of serum solution (FBS) at 37°C under electromagnetic stirring. After the incubation time (30 min, 3, 6, 24, 30, 48, 72 h) , the suspensions were centrifuged (13,000 rpm for 15 minutes) to separate NPs (with possible adsorbed serum protein and residual loaded 11 Cur) that precipitates from supernatant. The possible serum proteins adsorbed on NPs surface were quantified by colorimetric assay bicinchoninic acid (BCA) as described by manufacturer (Micro BCA protein assay kit composed of reagent A (alkaline tartrate-carbonate buffer), reagent B (bicinchonic acid solution) and reagent C (copper sulfate solution), purchased from Thermo Fisher Scientific Inc (Milan, Italy)) and subtracted from dried pellet to obtain the amount of NPs recovered after centrifugation. Residual Cur in NPs was extracted and quantified from pellet as described above.
Cell culture
Primary hippocampal cultures were prepared from rat brains (embryonic day 18) as described before ( 
Treatment of hippocampal cells
Aβ(1-42) peptides were initially dispersed in dH2O at a concentration of 1 mg/mL and thereafter stored at -20°C until use. Further dilutions of the peptides were performed in the culture medium (NB+++). Pure Cur was diluted to 1 mM in DMSO and stored at -20°C.
Further dilutions were performed in the culture medium (NB+++). To carry out the treatment with NPs, neurons were seeded in a total volume of 500 l per well (24 well plate) or 10 mL 
Immunocytochemistry
For immunofluorescence, the primary cultures were fixed with 4 % paraformaldehyde (PFA)/ 4% sucrose/PBS at 4°C for 20 min and processed for immunocytochemistry. After washing 3x5 min with 1x PBS containing 0.2% Triton X-100 at RT, blocking was performed with 10% FBS/ 1x PBS for 1 h at r.t. Subsequently, samples were incubated with primary antibody at r.t. for 2 h or at 4°C overnight. After a 3x5 min washing-step with 1x PBS, incubation with the secondary antibody coupled to Alexa488, Alexa568 or Alexa647 followed for 1 h. Cell nuclei were counterstained with DAPI and coverslips subsequently mounted using Vecta Mount (Vector Laboratories, USA).
Determination of cell death (apoptosis versus necrosis)
13 Toxicity of the samples after treatment was characterized by a healthy/apoptotic/necrotic cell detection kit (Promokine, Germany) using primary hippocampal rat cultures at DIV 14 on 24-well plates (in 500 L medium per well), according to the manufacturer's protocol. In brief, were used to increase the sample concentration. 500 μl of the supernatant were loaded into a filter and spun with 14,000 rpm for 10 min. The filter was then placed upside down in a new tube and spun again with 1,000 rpm for 10 min.
Western blotting: For western blot experiments, membrane-associated fractions from rat brains (P2) were used. Proteins were separated by SDS-PAGE and blotted onto Nitrocellulose membranes. Immunoreactivity was visualized using HRP-conjugated secondary antibodies and the SuperSignal detection system (Pierce, Upland, USA). 
Aβ aggregation assay
Aβ aggregation was determined using a Thioflavin T Beta-Amyloid (1-42) Aggregation Kit (SensoLyte, AnaSpec) according to the manufacturer's instructions. In brief, 900 μL of the assay buffer were added to 100 μL of Thioflavin to get a 2 mM solution. Aβ peptide was diluted in 1 mL of cold assay buffer and sonicated for 5 min, followed by centrifugation at 10,000 rpm for 5 min at 4 °C. To set up the fibrillation reaction, 10 μL of 2 mM Thioflavin were added into each well. Then, 85 μL of the Aβ solution and 5 μL of the test compounds (NPs) or control were added. As a control for pure Cur, DMSO was used. As control for the NPs, assay buffer was used. The fluorescence intensity was measured at 37°C with an excitation of 440 nm and an emission of 484 nm using a microplate reader (Tecan Infinite PRO 200, Tecan, Switzerland) every 10 min for up to three hours. 
Statistics
Statistical analysis was performed with SPSS version 20. All data are shown as mean ± SEM.
For comparisons, one-way analysis of variance (ANOVA) was performed followed by post hoc tests for within group comparisons (Bonferroni test). Statistically significant differences are indicated in the figures by * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.
Immunocytochemistry -Acquisition and evaluation of all images were performed under "blinded" conditions. 10 cells of each condition were imaged. All signals within the optic fields were quantified in the following way: Fluorescence images were obtained with an upright Axioscope microscope equipped with a Zeiss CCD camera (16 bits; 1280x1024 ppi) using Axiovision software (Zeiss). Quantification was performed using ImageJ 1.49o.
Western blot quantification -Evaluation of bands was performed using ImageJ. Three independent experiments were performed. The individual bands were selected and the integrated density was measured. Bands were normalized to β-actin and the ratios averaged and tested for significance. For Dot blot quantification, signals of individual spots were selected and the integrated density was measured.
Results
Formulation and characterization of novel nanocarriers
The chemico-physical and technological characterization of samples is reported in Fig. 1 . All
NPs were characterized in terms of size, surface charge, residual amount of surfactant and yield of preparation. All samples, independently of functionalization and/or loading, were featured by the hydrodynamic diameters (Z-average) around 200-250 nm and relatively narrow size distributions (polydispersivity, PDI<0.1), favorable for a systemic administration (Fig. 1A) . Un-modified NPs exhibit high negative value of ζ-pot (-22 mV) owing to the exposure of the carboxylic group of PLGA that indicates high electric charge on the surface of the NPs, which is responsible for the strong repulsive forces amongst the particles that prevents their aggregation in water. The functionalization with g7 (g7-NPs) significantly alters the ζ-pot value of NPs, reducing the negativity of their surface (about -13 mV); g7-NPsCur maintained the surface charge of g7-NPs, suggesting the absence of drug adsorbed on the NP surface. The amount of residual surfactant was less than 8% of the total formulation mass and compatible with parenteral administration (Fig. 1A) . ESCA analysis, a versatile tool in NPs showed N signals indicating that the location of g7 is on the surface of NPs (Fig. 1B) .
AFM images of samples (g7-NPs and g7-NPs-Cur) (Fig. 1C) showed a defined and reproducible spherical morphology and smooth surface already observed for un-modified NPs (data not shown). The AFM diameters were in agreement with PCS data. The presence of residual surfactant could be responsible of some aggregation during the dehydration process (necessary for the analyses). All samples show a yield between 85 and 95%, which can be considered satisfactory.
From a technological point of view, g7-NPs Cur showed high drug loading capacity (LC) of about 3% (w/w) and an encapsulation efficiency (EE) of about 60% (Fig. 1A) . The release profile of Cur from NPs in simulated physiological condition (PBS buffer added of 50% v/v of serum, in respect of sink conditions) is reported in Fig. 1D . We observed an initial massive "burst release" (about 60-70%) followed by a second slow release phase. These data suggest the presence of a significant amount of drug in the outer part of the structure, able to rapidly diffuse into the medium. Cur incorporated in the core of NPs was completely diffused within 72 h probably as a consequence of the beginning of NPs degradation.
Additionally, we characterized the g7-NPs-Cur according their photo-physical proprieties (Fig. 1E) . After excitation at 405 nm, these NPs showed a large emission with a maximum at 510 nm, typical of Cur.
g7-NPs-Cur show no cell toxicity
In a first set of experiments, we evaluated whether the novel g7-NPs (loaded/unloaded) exert toxic effects on hippocampal neurons in vitro.
To that end, we tested the same amount of g7-NPs and g7-NPs-Cur. Fixed amounts of NPs (namely 46, 115 and 230 g of g7-NPs or g7-NPs-Cur), corresponding to the concentration of 10, 20 and 40 M of Cur in g7-NPs-Cur were applied to neurons at DIV 13 and the rate of apoptosis and necrosis was measured after 24 h ( Fig. 2A) . Irrespective of the concentration used, no significant increase in apoptotic cells was detected after 24 hours. Selecting a NPs concentration delivering at least 20 M Cur and various incubation times from 1 h to 7 d, similarly, no increase of apoptotic cells was visible (Fig. 2B) . To investigate, whether NPs induce necrosis rather than apoptosis, we applied again concentrations of NPs delivering at least 20 M Cur and evaluated the rate of necrosis after 24 h (Fig. 2C ) and 7 d (Fig. 2D) 
g7-NPs-Cur uptake into neurons
As proof of the affinity of g7-NPs-Cur to neurons, we investigated the cellular uptake by means of fluorescence analysis (Fig.3) . Since Cur is characterized by large emission spectra which could interfere with signals derived from immunocytochemistry, in order to minimize the interference, we selected as fluorocromes, very strong imaging tools (namely QDs), featured by a very unique and defined signal. Therefore, g7-(QD)-NPs-Cur (see supplementary for information regarding the formulation, Table S1 and Fig S2 for characterization) were incubated with neurons for 3 hr. Data reveled that, on average, 75%
(data not shown) of the intracellular nanoparticles co-localized with Clathrin positive signals and we could claim that this output strongly agree with previous published data which described the cellular interaction of g7-NP (unloaded) (Vilella et al., 2015) mediated by clathrin pathways. Moreover, this result is also underlining the fact that the presence of even little amounts of Cur adsorbed onto the NPs surface did not interfere with the efficiency and dynamic of cells interaction.
Increased levels of Cur do not result in cellular toxicity
As previously evidenced, after exposure of cells to Cur loaded g7-NPs, the g7-NPs are readily taken up into cells. The resulting increase in intracellular and extracellular Cur concentration did not produced significant increase in cell death after 24 h and up to 7 d (Fig. 4A) (Fig. 4B ) and 7 d (Fig. 4C ) of treatment.
One proposed action of Cur is to act as scavenger of free radicals and thus reduce oxidative stress (Rajeswari, 2006) . Therefore, in a next set of experiment, we induced oxidative stress by addition of H2O2 and FeCl2 (Fenton reaction) ( Fig. 4D and 4E) . One day after the treatment, oxidative stress was measured by CellRox ® staining. Neurons showed a significant increase of oxidative stress after treatment compared to untreated cells (one-way ANOVA: F = 8.554, p < 0.001). However, cells treated for 30 min and 1 day with Cur did not present 20 such an increase. Cur also acted on untreated control cells hinting towards a reduction of oxidative stress endogenously present in control cultures (Fig. 4D) (Bonferroni post hoc test revealed significant differences between control and control with increased oxidative stress, and all Cur treatment groups p < 0.001) Delivery of Cur by g7-NPs had the same protective effect even after 7 d of treatment (Fig. 4E) (one-way ANOVA: F = 18.542, p < 0.001;
Bonferroni post hoc test revealed significant differences between control and control with increased oxidative stress, and control and g7-NPs-Cur treatment groups p < 0.001).
Modification of Aβ pathology by Cur loaded g7-NPs in vitro
Given the promising activity of Cur regarding oxidative stress and Aβ disaggregation (Yang et al., 2005) , in a next set of experiments, we evaluated whether Cur and Cur delivered by g7-NPs indeed was able to influence the cellular pathology induced by the presence of Aβ peptides in vitro. To that end, we incubated primary hippocampal neurons with 1, 10 and 100 µM of monomeric Aβ for 24 hours and confirmed a significant effect on cell viability after exposure of cells to 10 and 100 µM Aβ (Fig. 5A) . Ethanol was used as positive control (oneway ANOVA: F = 6.139, p < 0.001; Bonferroni post hoc test revealed significant differences between control vs. EtOH control p = 0.003; control vs. Aβ10µM p = 0.07; control vs. Aβ100µM p = 0.0002). Next, we investigated whether this effect on cell health can be modified by additional exposure of cells to Cur and g7-NPs-Cur (Fig. 5B) . Our results show that after 7 d of treatment, exposure of cells to Aβ again leads to a reduction in cell health. The addition of Cur or g7-NPs-Cur to these cultures partly restores cell health (seen as trend) (Fig. 5B) .
To answer the question, whether a positive effect of Cur is realized via altered Aβ aggregation, we again treated neurons with 100 µM Aβ and Cur and Cur delivering g7-NPs. After 7 d, the cell culture medium containing extracellular Aβ aggregates was removed and analyzed by 21 native Western Blot and anti-Aβ labeling (Fig. 5C) . A reduction in higher order Aβ aggregates was visible in conditions with exposure to Cur.
To confirm the reduction in Aβ aggregates by g7-NPs-Cur, we performed a thioflavin T based ELISA assay. An increase of fluorescence signal is correlated with an increase of Aβ42 fibril formation. As control, inhibitors of Aβ aggregation (Morin/Phenol Red) were used (Fig. 5D) .
The results show that co-incubation of Aβ with g7-NPs-Cur leads to a significant reduction of the observed Aβ aggregation and disaggregation was observed (one-way ANOVA: F = 166.839, p < 0.0001; Bonferroni post hoc test revealed significant differences between all groups p < 0.001). Moreover, unloaded g7-NPs increased Aβ aggregation at short time. This finding is not surprising since, as described by Radic and coworkers (Radic et al., 2015) , nanoparticles, in function of both their properties and the experimental conditions (concentration, ratio with A peptides etc) could be able to initially attract peptides promoting A aggregation onto the NP surface due to increased local protein concentration on the surface and destabilization of the folded state. However, at longer time-points, a further increase in NPs-peptide attraction could lead to a decrease of amyloid fibrils stability and to a reduction of their lateral diffusion on the NP surface, necessary for peptide conformational changes and self-association, thus prohibiting amyloid aggregation.
To further verify these findings, we used Aβ conformation dependent antibodies (OC antibody) that specifically recognize distinct assembly states of amyloids, including prefibrillar oligomers and fibrils. The OC antibody is able to recognize fibrillary oligomers that are immunologically distinct from prefibrillar oligomers (Kayed et al., 2007) . Dot blot analysis shows the presence of fibrillary oligomers in all cultures exposed to Aβ. As indicated by the previous results, the immune-reactive signal of OC antibody is significantly reduced by treatment with Cur and g7-NPs-Cur ( 
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Finally, as the loss of synapses may be the best cellular correlate to the cognitive impairments observed in AD patients, we assessed the ability of g7-NPs-Cur to prevent the decrease in synapse density observed after exposure of neurons to Aβ (Grabrucker et al., 2011b) . The mean number of synapses (Bassoon immunoreactive puncta) per dendrite length was measured 7 d after treatment with 10 µM Aβ (Fig. 5H) . As expected, a reduction can be observed in neurons exposed to Aβ. Interestingly, although not significant, a trend towards a rescue is observed in neurons treated with g7-NPs-Cur.
Discussion
Extracellular and intracellular protein aggregates are disruptive for synaptic function and cell health and are broadly held to be the major culprit of brain dysfunction underlying AD.
Developing treatment strategies aiming to reduce protein aggregation and propagation are therefore highly desired goals. it is indeed possible that Cur ameliorates inflammatory processes in AD brains.
In conclusion, reduced oxidative stress, inflammation and plaque load are the major outcomes observed in in vitro experiments confirming that the g7-NPs-Cur provided an efficient delivery for loaded Cur and proved a promising carrier candidate for treating AD.
Although further conclusions can be drawn only after a complete in vivo study in AD animal models, the results of this preliminary study suggest the potential role of surface modified loaded nanoparticles in stabilizing Cur, potentially solving the problem of administration and potentiating the effect of Cur against Aβ related toxicity. 
